The SPM5 results would suggest that hippocampal atrophy could potentially be a useful biomarker of preclinical AD in CN participants; likely reflecting the concurrent presence of hippocampal tau and neocortical Aβ deposition (Chetelat et al., 2010) in these participants. The gene discussed is MAPT; the disease is Atrophy.